University of Nottingham and BioFocus sign compound management agreement
Advertisement
BioFocus announced that its Compound Focus, Inc. subsidiary has signed a compound management services agreement with the University of Nottingham, UK. Under the terms of this agreement, Compound Focus will select, source, acquire, perform quality control checks and reformat a compound collection before returning to the Managed Chemical Compound Collection (MCCC) at the University of Nottingham. These services will be provided by Compound Focus’ compound management facility in South San Francisco, USA.
“In addition to aspects of compound management, the University of Nottingham has accessed BioFocus’ expertise in computational chemistry to aid compound selection,” said Scott Synder, Compound Focus General Manager. “The agreement not only demonstrates our ability to perform compound management on a global scale but also to integrate other aspects of the BioFocus offering to help achieve our clients’ objectives.”
Professor Peter Fischer, Director of the Centre for Biomolecular Sciences at the University of Nottingham commented: “In the first instance we sought to acquire a base collection as a maximally diverse subset of the vast number of screening compounds available from commercial sources. After considering a number of procurement options, we chose to work with BioFocus, which combines leading expertise in both chemoinformatics and in compound management, to assemble this base collection for us.”
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
ProBioGen enters into an evaluation programme with major vaccines company for the testing of cell lines
How to use antibodies to control chemical reactions - Researchers developed a strategy to synthesize functional molecules with specific diagnostic antibodies
Novel gene variants identified in male breast cancer
Ariadne Genomics and Jubilant Biosys Announce Strategic Alliance - Providing Curated Metabolic, Signaling, and Disease Pathway Databases as an Add-on to Pathway Analysis Software
Multiplicom receives €200,000 grant for novel non-invasive pre-natal test - IWT grant to support development of early aneuploidy detection during pregnancy
AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
